Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · TB-500Weak / none
PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo.
This is a preclinical drug-development study of full-length thymosin β4 — the parent molecule of the TB-500 fragment tracked here — reformulated as a PEGylated, thiol-site-specific prodrug (PEG-rTβ4) to extend its circulating half-life. In a rodent myocardial-infarction model, researchers reported the long-circulating construct was associated with reduced myocardial remodeling, improved cardiac function, greater new-vessel formation and less cell death, signaling through an Akt/Bcl-2/caspase-3 pathway. The work is engineering-forward: its central claim is druggability (supply, purity, half-life), not human efficacy. These are preclinical in-vivo findings; human data are needed before clinical conclusions can be drawn — and the authors themselves note no thymosin β4 drug has been approved despite a decade of trials. Weight this as an early manufacturing-and-mechanism signal for the thymosin β4 class, not as evidence in people.
Bioengineering & translational medicinen=—AnimalJul 1, 2026 - Study · KisspeptinWeak / none
Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
This study is not a clinical or pharmacological investigation — it is a doping-control analytical methods paper, and should be read as such. Researchers developed and validated a streamlined workflow capable of detecting 54 prohibited substances, including BPC-157 and TB-500, across dried blood spots, serum, and plasma using a single microextraction step followed by liquid chromatography coupled with high-resolution mass spectrometry. The analytical performance was satisfactory by laboratory standards: detection limits ranged from 0.05–1.25 ng/mL, no carry-over was observed, and matrix effects were modest (5–33%). Notably, dried blood spot matrices preserved all compounds for the full study duration under non-refrigerated conditions — a meaningful practical advantage for anti-doping sample logistics. For readers tracking BPC-157 and TB-500 specifically: the stability data are striking. Both peptides showed complete degradation in serum within one week at room temperature or refrigerator temperature — a finding with direct implications for detection windows in anti-doping contexts. Dried matrices retained detectability throughout. This paper contributes nothing to the...
The Analystn=——Jun 22, 2026 - Study · TB-500Weak / none
Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function.
A mouse study of thymosin beta-4 (the parent peptide of TB-500) as an add-on to the antibiotic ciprofloxacin in Pseudomonas bacterial keratitis. Researchers report that the Tβ4-plus-ciprofloxacin combination was associated with better visual acuity, contrast sensitivity, corneal sensitivity and nerve regeneration than antibiotic or Tβ4 alone, restoring nerve density toward uninfected levels. The novel angle is functional visual and nerve endpoints rather than just wound closure, which strengthens it relative to structure-only studies. Key caveats: this is a rodent infection model with small groups, it tests native Tβ4 (not the TB-500 synthetic fragment community users inject), and the benefit appears only in combination with an antibiotic, not as monotherapy. Tβ4's ophthalmic wound-healing signal is one of its more developed lines, but this specific finding is preclinical. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Investigative ophthalmology & visual sciencen=—AnimalJun 1, 2026 - Study · SS-31Weak / none
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
This narrative review in Sports Medicine surveys the pharmacological profiles, regulatory standing, and safety data for eleven peptides marketed to athletes and patients seeking injury recovery — ranging from FDA-approved tesamorelin to unapproved compounds such as BPC-157, TB-500, and MOTS-c. The authors' central finding is that a substantial regulatory gap exists: while some peptides (tesamorelin, sermorelin historically) have cleared rigorous approval processes for specific indications, many others circulate in a gray market supported primarily by animal-model data and amplified by social media. A narrative review design is worth flagging. Unlike a systematic review or meta-analysis, it does not involve exhaustive literature search protocols or pooled effect-size estimates, which means it reflects editorial judgment about which evidence to emphasise. That is appropriate for a broad landscape survey but limits the precision of any efficacy conclusions. The key caveat — which the authors acknowledge directly — is that favorable preclinical signals in rodent tissue-repair and metabolic models do not reliably translate to human outcomes. The review also raises an...
Sports medicine (Auckland, N.Z.)n=——Apr 12, 2026 - Study · Thymosin Alpha-1Weak / none
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation.
This narrative review in Integrative Medicine surveys the mechanistic rationale and existing evidence for several peptides — thymosin alpha-1, thymosin beta-4, BPC-157, and growth hormone secretagogues — as potential adjuncts in thyroid disorders, particularly Hashimoto's thyroiditis. The authors' own framing is appropriately cautious: the evidence base consists primarily of preclinical investigations, mechanistic studies, and early exploratory clinical reports, not thyroid-focused randomised controlled trials. As a narrative review, this study synthesises existing literature rather than generating new data — which means its conclusions are shaped by what research already exists, including its gaps. Narrative reviews are also susceptible to selection bias in ways that systematic reviews with predefined search protocols are not. The peptide context reinforces the authors' restraint. Thymosin alpha-1 carries the strongest human evidence base of the group, but that evidence covers hepatitis and oncology indications — not thyroid disease. BPC-157 remains almost entirely preclinical. The thyroid-specific evidence gap the review identifies is real and significant. Readers should...
Integrative medicine (Encinitas, Calif.)n=——Apr 1, 2026 - Study · TB-500Weak / none
Thymosin beta 4: An emerging therapeutic candidate for kidney diseases.
A narrative review of thymosin beta-4 (the parent molecule of TB-500) and its fragment Ac-SDKP in kidney injury and repair. It is a synthesis, not new data: the authors map proposed mechanisms — cytoprotective, anti-inflammatory and antifibrotic actions — across acute and chronic kidney injury models, and, to their credit, flag disparate and even bidirectional effects on fibrosis rather than presenting a clean story. That candour is worth noting. As a review it carries no more evidentiary weight than the mostly preclinical studies it summarises, and the authors themselves list the open challenges: validating efficacy in more clinically relevant models, overcoming the peptide's instability, and completing safety assessments. In other words, this is an early-stage, hypothesis-level case for a kidney application, not evidence of clinical benefit. Note TB-500 is a synthetic fragment distinct from the native Tβ4 much of this literature concerns. Human data are needed before clinical conclusions can be drawn.
Peptidesn=——Jan 1, 2026 - Study · TesamorelinWeak / none
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
This narrative review in the American Journal of Sports Medicine takes an appropriately cautious inventory of injectable peptide therapy for orthopaedic and sports medicine — a field where patient demand has outpaced clinical evidence considerably. The authors surveyed BPC-157, TB-4/TB-500, CJC-1295 plus ipamorelin, tesamorelin, and GHK-Cu via PubMed and found a consistent pattern: promising preclinical signals, thin or absent human data, and unresolved questions around dosing, frequency, and duration for every compound reviewed. The review's conclusions align well with the broader evidence landscape for these peptides. BPC-157's lone human data point is a methodologically limited case series. Tesamorelin, the most regulation-hardened compound in the group with FDA approval and Phase III RCT backing, earned that standing for HIV-associated lipodystrophy — a narrow indication with no orthopaedic carryover. The murine muscle data for CJC-1295 plus ipamorelin is mechanistically interesting but cannot be extrapolated to clinical use. As a narrative review, this paper synthesises existing literature rather than generating new data — it reflects the state of evidence rather than...
The American journal of sports medicinen=——Jan 1, 2026 - Study · DSIPWeak / none
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
This narrative review, published in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, surveys the mechanistic rationale for using therapeutic peptides — including BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295, tesamorelin, sermorelin, semax, selank, and epitalon — in orthopaedic and musculoskeletal contexts. As a narrative review, it synthesises existing literature rather than generating new data; it carries no experimental controls, no patient cohort, and no statistical analysis of outcomes. Readers should weight it as an expert-curated overview, not as clinical evidence. The review's own authors acknowledge the central limitation plainly: preclinical findings are promising, but clinical trials are currently lacking. That candid admission matters. For most peptides covered — BPC-157, TB-500, ipamorelin, and epitalon in particular — the mechanistic picture is built almost entirely on rodent and in-vitro models. Tesamorelin is the notable exception, carrying FDA approval for HIV-associated lipodystrophy on the basis of Phase III RCT data, though that evidence does not transfer to orthopaedic applications. The review is useful as a...
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviewsn=——Jan 1, 2026 - Study · TirzepatideWeak / none
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
This narrative review from Frontiers in Aging maps nine therapeutic peptides across aging-related domains — metabolic function, telomere biology, tissue repair, neuroprotection, GH modulation, and sexual function. The authors drew on 20 primary sources selected from PubMed, Scopus, and regulatory databases through January 2026. The core finding is an evidence stratification most readers of this space already sense: FDA-approved agents (tirzepatide, bremelanotide) rest on large-scale registration-quality trial data, while investigational peptides — epitalon, BPC-157, TB-500, Semax, GHK-Cu, CJC-1295, ipamorelin — show mechanistically interesting but methodologically limited signals, predominantly from preclinical models or small, often non-replicated studies. The critical caveat is the design itself. Narrative reviews are synthesis without meta-analytic rigour; the 20-source selection pool is modest for a field this broad, and the review does not appear to have applied formal quality-grading criteria. Conclusions therefore reflect the authors' judgment rather than a systematic evidence synthesis. For readers tracking investigational peptides: the review adds conceptual framing...
Frontiers in agingn=——Jan 1, 2026 - Study · TB-500Mixed
Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.
This is the most clinically significant study in the batch — and it needs careful reading. Alongside mouse ischemia-reperfusion work, it includes a randomised, double-blind, placebo-controlled trial of recombinant human thymosin beta-4 in 96 STEMI (heart attack) patients after stent treatment. The headline is mixed, not positive: infarct area was significantly smaller in the subgroup dosed early (within 8 hours of PCI, n=43) at 90 days, but across the full 96-patient cohort there was no significant difference versus placebo. That distinction matters — a subgroup signal is hypothesis-generating, not a demonstration of benefit, and the authors themselves call for further rigorous trials. The mechanistic work (ErbB2/Raf1 signalling, reduced apoptosis) is coherent and the human trial is a genuine step above the rest of this literature, but the agent studied is recombinant human Tβ4, not the synthetic TB-500 fragment. Weigh this as promising but unproven early human evidence. Note the overall primary endpoint was not met.
Cardiovascular researchn=—HumanDec 31, 2025 - Study · TB-500Weak / none
Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing.
This study is really about protein engineering: researchers fused two thymosin beta-4 units into a single “tandem” peptide (tTβ4) with two actin-binding domains, aiming to fix Tβ4's short half-life and high synthesis cost. In human corneal cells and a mouse alkali-burn model, they report tTβ4 was associated with greater cell migration, better corneal wound healing and less scarring than standard Tβ4, and that it can be made by bacterial fermentation. Read this as a proof-of-concept for a redesigned molecule, not a validation of TB-500 as used in the community — tTβ4 is a novel construct, and the comparator Tβ4 is the native peptide, not the TB-500 fragment. Endpoints are in-vitro and short-term rodent wound outcomes. The corneal wound-healing line is one of Tβ4's more developed signals, but this remains preclinical. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Investigative ophthalmology & visual sciencen=—AnimalNov 3, 2025 - Study · TB-500Weak / none
Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids.
A laboratory study using human iPSC-derived cerebral organoids (“mini-brains”) carrying familial Alzheimer mutations, plus 5xFAD model mice. Researchers report that the gene TMSB4X, which encodes thymosin beta-4, was expressed at lower levels in the diseased organoids and in Alzheimer patients' excitatory neurons, and that adding Tβ4 was associated with rescue of the neurodevelopmental deficits and reduced amyloid-beta formation seen in the organoids, with corroborating effects in the mice. This is an interesting target-identification finding, but it sits at the earliest translational stage: an organoid model plus mice, measuring cellular and molecular endpoints, not cognitive outcomes. Tβ4's neurological effects are among its more speculative claims, and the peptide here is native Tβ4, not the TB-500 fragment. These are preclinical, mechanistic signals; human data are needed before any clinical conclusions can be drawn.
Stem cell reportsn=—In vitroSep 9, 2025 - Study · TB-500Weak / none
Living myocardial slices as a model for testing cardiac pro-reparative gene therapies.
Worth flagging that this study is not really about thymosin beta-4 as a therapy. Its subject is a research model — living myocardial slices (thin ex-vivo heart tissue) — proposed as a cheaper, more human-relevant alternative to mice for testing cardiac gene therapies. Tβ4 appears only as one of two pro-angiogenic factors (alongside prothymosin alpha) secreted downstream when the delivered gene ZEB2 is expressed. Researchers report that viral delivery of these factors produced similar gene-expression changes and angiogenic responses in both the tissue slices and mice, supporting the slices as a viable model. So the takeaway concerns methodology, not the effects of Tβ4 or of TB-500 in people. Treat any peptide-specific inference as incidental. These are preclinical, ex-vivo and animal findings; they say little about human peptide therapy, and human data would be needed before any clinical conclusions.
Molecular therapy : the journal of the American Society of Gene Therapyn=—In vitroJul 2, 2025 - Study · TB-500Weak / none
Equine Doping Controls of Thymosin β 4: A Population Study and Strategy for Misuse Detection.
This is a doping-control and analytical-chemistry study, not an efficacy trial. Its purpose is detection: establishing baseline endogenous Thymosin beta-4 (TB4) concentrations in racing-horse blood and showing that a synthetic-origin impurity can be identified after a single dose of a TB4 product. Researchers reported that natural TB4 levels did not vary meaningfully by sex, age or breed, and, a useful practical caveat, that TB4 rises quickly in blood stored cold if cells are not separated, a sample-handling artefact. For AllAboutAminos readers, the value here is context rather than benefit: it documents that TB4/TB-500-type products are circulating and banned in equine sport (by the IFHA, FEI and WADA), and that testing methods are catching up. It says nothing about whether TB-500 helps or harms, since no health outcome was measured, and it concerns horses, not humans. Read it as a marker of the compound's regulatory and detection landscape.
Drug testing and analysisn=—AnimalJul 1, 2025 - Study · TB-500Weak / none
Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals.
A mouse mechanistic study probing how thymosin beta-4 might reduce scarring after heart injury. After permanent coronary ligation, with or without systemic Tβ4, researchers profiled heart microRNAs and report that Tβ4 was associated with increased miR-139-5p and reduced ROCK1, a protein whose inhibition is beneficial in several cardiac conditions; they suggest Tβ4 may act partly as an indirect ROCK1 inhibitor and can dampen the fibroblast-to-myofibroblast switch that drives scarring. This is a mechanism-focused animal and cell study, not an outcomes trial — it helps explain earlier reports of Tβ4's cardiac effects rather than establishing clinical benefit. Caveats: mouse model, molecular endpoints, and the peptide is native Tβ4, not the synthetic TB-500 fragment. It fits a broader Tβ4 cardiac-repair literature whose human trials have been mixed. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
International journal of molecular sciencesn=—AnimalApr 26, 2025 - Study · TB-500Weak / none
Inhaled exogenous thymosin beta 4 suppresses bleomycin-induced pulmonary fibrosis in mice via TGF-β1 signalling pathway.
A mouse study of inhaled (nebulised) recombinant human thymosin beta-4 in bleomycin-induced pulmonary fibrosis, a standard lung-scarring model. Researchers report that aerosolised rhTβ4 was associated with reduced fibrosis at early, mid and late dosing stages, measured by hydroxyproline, lung function and histology, and that in cell studies it suppressed fibroblast proliferation, migration and activation and an epithelial-mesenchymal transition, apparently via the TGF-β1 pathway. The inhaled route is a practical touch for a lung target, and the antifibrotic mechanism is coherent with Tβ4 biology. Caveats: bleomycin is an induced model that imperfectly mirrors human idiopathic pulmonary fibrosis, endpoints are rodent and cellular, and this is native rhTβ4, not the TB-500 fragment. Encouraging as a preclinical signal for an antifibrotic application, but not clinical proof. These are preclinical findings; human data are needed before any clinical conclusions.
The Journal of pharmacy and pharmacologyn=—AnimalApr 3, 2025 - Study · TB-500Weak / none
Study of Intracellular Peptides of the Central Nervous System of Zebrafish (Danio rerio) in a Parkinson's Disease Model.
This study is about naturally occurring intracellular peptide fragments in a zebrafish Parkinson's model, and thymosin beta-4 features only as the precursor protein for one of five fragments tested — it is not a study of Tβ4 or TB-500 as administered compounds. Researchers synthesised the five peptides, characterised their structure, found them non-cytotoxic in mouse and human cell lines, and report that all five helped recover motor function in 6-OHDA-injured zebrafish larvae after 24 hours, with three producing complete recovery of the induced motor impairment. Interesting as early neuropeptide screening, but the endpoints are short-term larval behaviour and the authors explicitly call the mechanism unknown and further study necessary. This is preclinical and only tangentially related to the intact Tβ4/TB-500 peptide; it should not be read as evidence about them. Human data would be needed before any clinical conclusions.
International journal of molecular sciencesn=—AnimalFeb 26, 2025 - Study · TB-500Weak / none
Enhancing fat graft survival: thymosin beta-4 facilitates mitochondrial transfer from ADSCs via tunneling nanotubes by upregulating the Rac/F-actin pathway.
A mechanistic cell study of thymosin beta-4 in the context of fat grafting. Researchers report that Tβ4 upregulated the Rac/F-actin pathway, increasing formation of “tunneling nanotubes” through which mitochondria transferred from adipose-derived stem cells to fat cells and new vessels — a process they associate with less oxidative stress, reduced cell death, better blood-vessel formation and improved graft retention. The mitochondrial-transfer mechanism is novel and fits Tβ4's known actin-regulating biology. But this is largely in-vitro (with grafting endpoints), measuring cellular processes rather than clinical outcomes, and the abstract does not quantify the retention benefit. It tests native Tβ4, not the TB-500 fragment used in the community. Read as an interesting mechanistic signal for tissue-engineering applications, not evidence of benefit in patients. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Free radical biology & medicinen=—In vitroFeb 16, 2025 - Study · TB-500Weak / none
Identification of glutamine as a potential therapeutic target in dry eye disease.
The headline of this study is glutamine metabolism, not thymosin beta-4. Researchers used Tβ4 in combination with mesenchymal stem cells as the best-performing dry-eye treatment in their rodent model, then worked backward to find why — identifying increased corneal glutamine as the key mediator, with the enzyme GLS1 as a control point. Tβ4 is thus a component of the combination, not the studied agent, and its individual contribution is not isolated here. The mechanistic work (metabolomic imaging, single-cell sequencing, GLS1 gain and loss) is thorough, but endpoints are cellular and rodent, and clinical benefit is not demonstrated. For readers interested in TB-500, this offers little peptide-specific evidence and concerns native Tβ4, not the synthetic fragment. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Signal transduction and targeted therapyn=—AnimalJan 22, 2025 - Study · TB-500Weak / none
Proteomic analysis of the human amniotic mesenchymal stromal cell secretome by integrated approaches via filter-aided sample preparation.
This is a methods-and-discovery proteomics study, and thymosin beta-4 appears only as one of several molecules detected — not as a tested therapy. Researchers profiled the secretome (secreted proteins and peptides) of human amniotic mesenchymal stromal cells using a filter-based fractionation method, and in the small-peptide fraction they identified fragments of thymosin beta-4 and beta-10 alongside collagen chains and metabolic enzymes, noting these are associated with wound healing and tissue repair. The contribution is analytical — a fuller molecular catalogue of this cell secretome — not any demonstration of what Tβ4 does. There are no functional or clinical endpoints here, and nothing specific to TB-500. For peptide readers this is essentially a mention: it confirms Tβ4 fragments are present in a regenerative cell product, nothing more. No efficacy or human outcome can be inferred, and human data would be needed before any clinical conclusions.
Journal of proteomicsn=—In vitroJan 6, 2025 - Study · TB-500Weak / none
Thymosin β4 Regulates Tissue Inflammatory Response in Mouse Nonalcoholic Fatty Liver Disease by Promoting Macrophage M2-Type Polarization.
A mouse study of fatty liver disease (NAFLD) reporting that Thymosin beta-4 (Tbeta4) shifted liver immune cells toward an anti-inflammatory M2 state, reduced liver inflammation and lipid build-up, and lowered liver-cell death, via a proposed STAT1/SOCS pathway. Knocking Tbeta4 down worsened the liver changes. These are preclinical findings, from a diet-induced rodent model plus supporting cell-culture work, and human data are needed before clinical conclusions can be drawn. Note that it studies the native protein Tbeta4, not TB-500, the synthetic fragment sold to the community; the two are not interchangeable. It is also worth reading alongside the cancer-progression literature on Tbeta4, where the same molecule is cast less favourably, a reminder that a broadly acting repair and immune signal can cut in different directions depending on tissue and context. Treat this as a hypothesis-generating signal for a specific liver model, not support for TB-500 use in people.
Journal of inflammation researchn=—AnimalJan 1, 2025 - Study · TB-500Weak / none
TMSB4X is a regulator of inflammation-associated ferroptosis, and promotes the proliferation, migration and invasion of hepatocellular carcinoma cells.
An important counterweight to the healing-focused Tβ4 literature. This cancer-biology study reports that TMSB4X — the gene encoding thymosin beta-4 — is overexpressed in hepatocellular carcinoma and, in liver-cancer cell lines, promoted cell viability, migration and invasion while suppressing ferroptosis (a form of cell death), positioning it as a potential pro-tumour driver and prognostic biomarker. This is the flip side of the peptide's regenerative reputation: the same actin- and survival-linked biology that may aid repair can, in a cancer context, favour tumour cell growth. The work is in-vitro plus bioinformatic modelling of patient datasets, so it is mechanistic and associative, not a clinical outcome study, and it concerns endogenous gene expression rather than administered TB-500. Still, it is a caveat worth weighing for anyone interested in this peptide. These are preclinical findings; human data are needed before clinical conclusions.
Discover oncologyn=—In vitroNov 18, 2024 - Study · TB-500Weak / none
Therapeutic potential of thymosin beta 4 in a variety of diseases.
No abstract was available for this item, so this note is based on the title and journal alone. It is a review article in the Asian Journal of Surgery titled 'Therapeutic potential of thymosin beta 4 in a variety of diseases.' As a narrative review, it summarises and interprets existing literature rather than reporting new experimental data, and its selection of sources and conclusions cannot be assessed without the full text. Readers should read the title's phrase 'therapeutic potential' as the framing of a review, not as evidence of demonstrated clinical benefit. It is worth remembering the broader landscape here: most thymosin beta-4 (Tβ4) evidence is preclinical, human data are limited to a small number of early-phase trials of the native peptide, and TB-500 is a synthetic fragment (Ac-LKKTETQ) whose specific effects have not been independently characterised in peer-reviewed human studies. Without the abstract, no specific findings can be reported.
Asian journal of surgeryn=——Nov 1, 2024 - Study · TB-500Weak / none
Thymosin β4 promotes zebrafish Mauthner axon regeneration by facilitating actin polymerization through binding to G-actin.
This is a preclinical in-vivo study in zebrafish larvae, using a single-axon injury model of Mauthner cells to probe how thymosin beta-4 (Tβ4) influences central nervous system axon regeneration. Researchers reported that knocking out Tβ4 impaired regeneration while overexpressing it promoted regeneration, and that the effect was mediated by Tβ4 binding G-actin to favour actin polymerisation. They also introduced a behavioural readout (the 'straight tail' phenomenon) that correlated with axon regrowth. The work is notable because it addresses a gap the authors themselves flag: prior Tβ4 axon-regeneration results, largely from cultured cells, had been contradictory, so an in-vivo model adds value. Weight it accordingly: zebrafish are a long way from human neurology, and the study manipulates endogenous Tβ4 genetically rather than administering TB-500, the synthetic Ac-LKKTETQ fragment sold in the community. These are mechanistic signals; human data are needed before clinical conclusions can be drawn. The authors' own framing of Tβ4 as a 'potential' drug candidate is speculative.
BMC biologyn=—AnimalOct 23, 2024 - Study · TB-500Weak / none
Thymosin β4 and β10 Expression in Human Organs during Development: A Review.
A narrative review summarising one group's body of work mapping where Thymosin beta-4 and beta-10 appear across human tissues from fetal development into later life, drawing on saliva, gingival fluid and post-mortem immunochemistry. It is descriptive biology, not an efficacy study: it charts expression patterns and speculates about the peptides' developmental roles, the so-called beta-thymosin enigma, rather than testing any intervention. As a review from a single lab, it inherits that group's framing and is best read as background on what these peptides are and where they act. For readers interested in TB-500 (a synthetic fragment of Tbeta4), it usefully underlines that Tbeta4 is a widespread, naturally occurring molecule with roles that are still being worked out, but it offers no data on supplementation, dosing, benefit or risk in people. Treat it as context on the peptide's basic biology, not as evidence for any use.
Cellsn=——Jun 27, 2024 - Study · TB-500Weak / none
In Vitro Study of Thymosin Beta 4 Promoting Transplanted Fat Survival by Regulating Adipose-Derived Stem Cells.
An in-vitro study, published in Aesthetic Plastic Surgery, using human adipose-derived stem cells (ADSCs) isolated from liposuction patients to probe how thymosin beta-4 (Tβ4) might support fat survival in fat-grafting procedures. Researchers reported that Tβ4 at 100 and 1000 ng/mL significantly increased ADSC proliferation from day one (p=0.017 and p=0.005), raised proliferation-related gene expression, improved the cells' resistance to induced cell death (p=0.011), and altered genes tied to blood-vessel formation and the Hippo signalling pathway. The findings are internally consistent and use human cells, which is a modest strength over rodent-cell work. But this is cell-culture only: it cannot demonstrate that grafted fat survives better in patients, and the effects are on isolated cells in a dish, not a clinical outcome. It also uses native Tβ4, not the synthetic TB-500 fragment. Weight it as a plausible mechanistic contribution to the fat-grafting hypothesis, not clinical evidence. These are preclinical findings; human outcome data are needed before clinical conclusions can be drawn.
Aesthetic plastic surgeryn=—In vitroJun 1, 2024 - Study · TB-500Weak / none
The subcommissural organ regulates brain development via secreted peptides.
A peer-reviewed study in Nature Neuroscience investigating the subcommissural organ (SCO), a little-understood brain gland, and its role in development, using mouse genetic models. Researchers genetically ablated SCO cells during embryonic development and observed severe hydrocephalus and defects in neuronal migration and axon/dendrite development. A peptidomic analysis identified three SCO-derived peptides — thymosin beta-4 (Tβ4), thymosin beta-10 and NP24 — and reintroducing them into the brain ventricles substantially rescued the defects. The relevance to TB-500 is indirect and mechanistic: it situates Tβ4 as one of several endogenous developmental signals, not as an administered therapeutic. This is basic developmental neuroscience in mice, not a study of Tβ4 supplementation or of the synthetic TB-500 fragment, and the rescue used a combination of three peptides, so Tβ4's individual contribution is not isolated here. Interesting for understanding native Tβ4 biology; it says little about community injection protocols. These are preclinical findings; human relevance is not established.
Nature neurosciencen=—AnimalJun 1, 2024 - Study · TB-500Weak / none
The subcommissural organ regulates brain development via secreted peptides.
This is the preprint (bioRxiv) version of the subcommissural-organ developmental study, and as a preprint it has not yet completed peer review — findings may change before formal publication. A peer-reviewed version of the same work appears in Nature Neuroscience. Researchers genetically ablated cells of the subcommissural organ (SCO) in developing mice, producing severe hydrocephalus and defects in neuronal migration and axon/dendrite development, then identified three SCO-secreted peptides — thymosin beta-4 (Tβ4), thymosin beta-10 and NP24 — whose reintroduction into the brain ventricles substantially rescued the defects. As with the published version, the connection to TB-500 is indirect: it frames native Tβ4 as one of several endogenous developmental signals, delivered as a three-peptide combination, not as an administered drug and not as the synthetic TB-500 fragment. Weight it as basic mouse developmental neuroscience, and as preprint-stage. These are preclinical findings; human relevance is not established, and the preprint status warrants extra caution.
bioRxiv : the preprint server for biologyn=—AnimalMar 31, 2024